UBS more constructive on CME Group following underperformance UBS is more constructive on CME Group following recent underperformance and said January volumes are off to a good start and activity should improve. The firm reiterates its Buy rating and $83 price target.
News For CME From The Last 14 Days
Check below for free stories on CME the last two weeks.
CME sued on claims high-frequency traders purchased access, Bloomberg says CME Group is facing a lawsuit by by three of its users who claim the company sold access to order information to high-frequency traders ahead of other market participants, according to Bloomberg, citing a complaint filed in Chicago federal court. Reference Link